Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Up 126.3% in July

Alzamend Neuro, Inc. (NASDAQ:ALZN) was the recipient of a large growth in short interest in July. As of July 31st, there was short interest totalling 17,200 shares, a growth of 126.3% from the July 15th total of 7,600 shares. Based on an average daily volume of 18,100 shares, the days-to-cover ratio is currently 1.0 days. Currently, 2.1% of the company’s shares are short sold.

Hedge Funds Weigh In On Alzamend Neuro

An institutional investor recently bought a new position in Alzamend Neuro stock. Virtu Financial LLC purchased a new stake in shares of Alzamend Neuro, Inc. (NASDAQ:ALZN) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 26,482 shares of the company’s stock, valued at approximately $26,000. Virtu Financial LLC owned about 0.38% of Alzamend Neuro at the end of the most recent reporting period. 49.61% of the stock is owned by institutional investors.

Alzamend Neuro Stock Performance

ALZN traded down $0.01 during trading on Wednesday, reaching $2.02. The company had a trading volume of 6,503 shares, compared to its average volume of 12,727. The firm’s 50-day simple moving average is $3.92 and its 200 day simple moving average is $6.74. The company has a market cap of $16.12 million, a price-to-earnings ratio of -2.01 and a beta of 0.03. Alzamend Neuro has a 12-month low of $1.84 and a 12-month high of $51.24.

About Alzamend Neuro

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.